TCR2 Therapeutics F/K oranı 2024

TCR2 Therapeutics ne yapıyor?

TCR2 Therapeutics Inc. is a biopharmaceutical company specialized in the development of cancer therapies. It was founded in 2015 by a team of scientists from the Dana-Farber Cancer Institute and the Memorial Sloan Kettering Cancer Center. TCR2 Therapeutics' business model is based on the development of T-cell therapies using T-cell receptors (TCRs). TCRs are receptors on the surface of T-cells that can recognize specific antigens on tumor cells. TCR2 Therapeutics focuses on the development of TCR-T-cell therapies that can directly attack and destroy tumor cells. TCR2 Therapeutics has divided its business into several divisions. The main division is the development of cancer therapies based on TCR-T-cells. The company uses a combination of gammaretroviral and lentiviral vectors to produce TCR-T-cells. These vectors serve as tools to introduce the TCR gene into T-cells and lead to the elimination of the self-inflicted disease. The first product developed by TCR2 Therapeutics is a TCR-T-cell therapy for the treatment of HPV-associated cancer. The product is currently in phase I clinical trials and is being tested on patients with advanced cervical cancer. TCR2 Therapeutics has also developed a platform technology that allows T-cell receptors (TCRs) to be targeted to specific tumor characteristics. This technology enables TCR2 Therapeutics to develop more precise and targeted TCR-T-cell therapies customized to patients' needs. The company has also formed a partnership with Medigene, a German biotechnology company, to develop TCR-T-cell therapies for cancer treatment based on the combination of TCRs and CARs. TCR2 Therapeutics has already raised several million dollars in funding to advance its research and development activities. Investors include Fidelity Management & Research Company, Bessemer Venture Partners, and MPM Capital. Overall, TCR2 Therapeutics has developed a promising business model based on the development of TCR-T-cell therapies for cancer treatment. The company has already achieved promising results and is expected to bring further therapies to the market in the future that have the potential to improve the lives of cancer patients. TCR2 Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.